Actinogen Medical Limited announced that it has appointed US-based Dr. Dana Hilt as Chief Medical Officer, effective immediate. Dr. Hilt assumes the CMO role from Professor Paul Rolan who will continue with the Company as Head of Clinical Pharmacology and Lead Physician, Depression. Dr. Dana C. Hilt MD has more than 25 years of drug development experience, primarily of Central Nervous System drugs.

Dr. Hilt has extensive experience in Phases 1 to 4 of development for conditions including Alzheimer's disease, depression, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, and other non-CNS conditions including CNS malignancies. Dr. Hilt was most recently the Chief Medical Officer at Frequency Therapeutics and has held senior development and management positions as Chief Medical Officer at several pharmaceutical companies, including Lysosomal Therapeutics, Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. Prior to that, Dr. Hilt worked with Amgen, establishing a Clinical Neuroscience Group that focused on the potential therapeutic applications of neurotrophic factors in degenerative neurologic diseases such as Parkinson's disease.

Dr. Hilt gained his medical degree from Tufts University School of Medicine in Boston and trained in internal medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital. He has held academic neurology positions at the University of Maryland and University of Southern California where he conducted molecular biological research, taught clinical neurology and basic neurobiology, and cared for patients with neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and ALS. Professor Paul Rolan MD is a clinical pharmacologist, internal medicine and pain management specialist and one of Australia's most experienced clinical trial investigators and drug developers.

He has extensive expertise in the development of medicines as principal investigator in more than 750 early phase proof-of-concept, clinical pharmacology, drug interaction and special patient groups studies. Professor Rolan continues to play a pivotal role in the XanaCIDD Phase 2 Depression clinical trial that measures the effects of Xanamem ® on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment.